Irritable bowel syndrome: Bacterial overgrowth - What's known and what to do

Current Treatment Options in Gastroenterology

Volumn 10, Issue 4, 2007, Pages 328-337

  Pimentel, Mark ^a   Lezcano, Sheila ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

METHANE; NEOMYCIN; PLACEBO; PROBIOTIC AGENT; PROKINETIC AGENT; RIFAXIMIN; TEGASEROD;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL OVERGROWTH; BACTERIUM CULTURE; BIFIDOBACTERIUM LONGUM INFANTIS; BREATH ANALYSIS; CLINICAL TRIAL; CONSTIPATION; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; FOLLOW UP; GASTROENTERITIS; HUMAN; IMMUNOMODULATION; INTESTINE MOTILITY; NONHUMAN; REVIEW; TREATMENT OUTCOME;

EID: 34547563881     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-007-0076-1     Document Type: Review

References (58)

1. Drossman DA, Sandler RS, McKee DL, et al: Bowel patterns among subjects not seeking health care. Gastroenterology 1982, 83:529-534.
2. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force: Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002, 97 (11 Suppl):S1-S5.
3. Whitehead WE, Holtkotter B, Enck P, et al.: Tolerance for rectosigmoid distension in irritable bowel syndrome. Gastroenterology 1990, 98:1187-1192.
4. Mertz H, Morgan V, Tanner G, et al.: Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology 2000, 118:842-848.
5. Drossman DA, Ringel Y, Vogt BA, et al.: Alterations in brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome. Gastroenterology 2003, 124:754-761.
6. Bülbring E, Lin RC: The effect of intraluminal application of 5-hydroxytryptamine and 5-hydroxytryptophan on peristalsis; the local production of 5-HT and its release in relation to intraluminal pressure and propulsive activity. J Physiol 1958, 140:381-407.
7. Bülbring E, Crema A: Observations concerning the action of 5-hydroxytryptamine on the peristaltic reflex. Br J Pharmacol 1958, 13:444-457.
8. Bülbring E, Crema A: The action of 5-hydroxytryptamine, 5-hydroxytryptophan and reserpine on intestinal peristalsis in anaesthetized guinea pigs. J Physiol 1959, 146:29-53.
9. Costa M, Furness JB: The peristaltic reflex: an analysis of the nerve pathways and their pharmacology. Naunyn Schmiedeberg's Arch Pharmacol 1976, 294:47-60.
10. Bearcroft CP, Perrett D, Farthing MJ: Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 1998, 42:42-46.
11. Camilleri M, Chey WY, Mayer EA, et al.: A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001, 161:1733-1740.
12. Camilleri M, Northcutt AR, Kong S, et al.: Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000, 355:1035-1040.
13. Müller-Lissner SA, Fumagalli I, Bardhan KD, et al.: Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001, 15:1655-1666.
14. Novick J, Miner P, Krause R, et al.: A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002, 16:1877-1888.
15. Pimentel M, Chow EJ, Lin HC: Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000, 95:3503-3506.
16. Pimentel M, Chow EJ, Lin HC: Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003, 98:412-419.
17. Walters B, Vanner SJ: Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol 200S, 100:1566-1570.
18. Nucera G, Gabriella M, Lupascu A, et al.: Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005, 21:1391-1395.
19. McCallum R, Schultz C, Sostarich S: Evaluating the role of small intestinal bacterial overgrowth (sibo) in diarrhea predominant irritable bowel syndrome (IBS-D) patients utilizing the glucose breath test (gbt) [abstract]. Gastroenterology 2005, 128:A460.
20. Lupascu A, Gabrielli M, Lauritano EC, et al.: Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther 2005, 22:1157-1160.
21. Cuoco L, Salvagnini M: Small intestine bacterial over-growth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol 2006, 52:89-95.
22. Dunetz M: Gut Ecology. Edited by Hart AL, Stagg AJ, Graffner H, et al.: Trowbridge, England: Cromwell Press; 2002.
23. Posserud I, Stotzer PO, Einar S, et al.: Altered counts of small bowel bacteria in patients with irritable bowel syndrome. Gut 2007, In press.
24. Thompson WG: The functional gastrointestinal bowel disorders. In The Functional Gastrointestinal Disorders. Edited by Drossman DA. Boston: Little Brown; 1994:117-134.
25. Thompson WG, Longstreth GF, Drossman DA, et al.: Functional bowel disorders and functional abdominal pain. Gut 1999, 45(Suppl 2):II43-II47.
26. Longstreth GF, Thompson WG, Chey WD, et al.: Functional bowel disorders. Gastroenterology 2006, 130:1480-1491.
27. Kaufmann SH: Robert Koch, the Nobel Prize, and the ongoing threat of tuberculosis. N Engl J Med 2005, 353:2423-2426.
28. Di Stefano M, Malservisi S, Veneto G, et al.: Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2000, 14:551-556.
29. Attar A, Flourie B, Rambaud JC, et al.: Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 1999, 117:794-797.
30. Pimentel M, Park S, Mirocha J, et al.: The effect of a nonabsorbed oral antibiotic (Rifaximin) on the symptoms of the irritable bowel syndrome. A randomized trial. Ann Intern Med 2006, 145:557-563.
31. Kellow J, Lee OY, Chang FY, et al.: An Asia-Pacific, double blind, placebo controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003, 52:671-676.
32. Pimentel M, Mayer AG, Park S, et al.: Methane production during lactulose breath test is associated with gastrointestinal disease presentation. Dig Dis Sci 2003, 48:86-92.
33. Soares AC, Lederman HM, Fagundes-Neto U, et al.: Breath methane associated with slow colonic transit time in children with chronic constipation. J Clin Gastroenterol 2005, 39:512-515.
34. Stephen AM, Wiggins HS, Englyst HN, et al.: The effect of age, sex and level of intake of dietary fiber from wheat on large-bowel function in thirty healthy subjects. Br J Nutr 1986, 56:349-361.
35. Cloarec D, Bornet F, Gouilloud S, et al.: Breath hydrogen response to lacrulose in healthy subjects: relationship to methane producing status. Gut 1990, 31:300-304.
36. Pimentel M, Lin HC, Enayati P, et al.: Methane, a gas produced by enteric bacteria, slows intestinal transit and augments ileal contractile activity. Am J Physiol 2006, 290: G1089-G1095.
37. Pimentel M, Chatterjee S, Chow EJ, et al.: Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci 2006, 51:1297-1301.
38. Chatterjee S, Park S, Low K, et al.: The degree of breath methane production in IBS correlates with the severity of constipation. Am J Gastroenterol 2007, 102:837-841.
39. Li E: Bacterial overgrowth. In Textbook of Gastroenterology. Edited by Yamada T. New York: Lippincott-Raven; 1995:1673-1680.
40. Parson AJ, Brzechwa-Ajdukiewicz A, McCarthy CF: Intestinal pseudo-obstruction with bacterial overgrowth in the small intestine. Am J Dig Dis 1969, 14:200-205.
41. Kahn IJ, Jeffries GH, Sleisenger MH: Malabsorption in intestinal scleroderma: correction with antibiotics. N Engl J Med 1966, 274:1339-1344.
42. Vantrappen G, Janssens J, Hellemans J, Ghoos Y: The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine J Clin Invest 1977, 59:1158-1166.
43. Szurszewski JH: A migrating electric complex of the canine small intestine. Am J Physiol 1969, 217:1757-1763.
44. Pimentel M, Soffer EE, Chow EJ, Lin HC: Lower frequency of MMC is found in IBS subjects with abnormal breath test suggesting bacterial overgrowth. Dig Dis Sci 2002, 47:2639-2643.
45. Neal KR, Hebden J, Spiller R: Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis, and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997, 314:779-782.
46. Parry SD, Stansfield R, Jelley D, et al.: Welfare MR. Is irritable bowel syndrome more common in patients presenting with bacterial gastroenteritis? A community-based, case-control study. Am J Gastroenterol 2003, 98:238-241.
47. Barber R, Blakey A: Prevalence of gastrointestinal symptoms after bacterial gastroenteritis: study did not include control group. BMJ 1997, 314:1903.
48. Neal KR, Barker L, Spiller RC: Prognosis in post-infectious irritable bowel syndrome: a six year follow up study. Gut 2002, 51:410-413.
49. Okhuysen PC, Jiang ZD, Carlin L, et al.: Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol 2004, 99:1774-1778.
50. Mearin F, Perez-Oliveras M, Perello A, et al.: Dyspepsia and irritable bowel syndrome after a Salmonella outbreak: one-year follow-up cohort study. Gastroenterology 2005, 129:98-104.
51. Spiller RC, Jenkins D, Thornley JP, et al.: Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000, 47:804-811.
52. Halvorson HA, Schlett CD, Riddle MS: Postinfectious irritable bowel syndrome - a meta-analysis. Am J Gastroenterol 2006, 101:1894-1899.
53. Dunlop SP, Jenkins D, Neal KR, Spiller RC: Relative importance of enterochrornaffin cell hyperplasia, anxiety and depression in post-infectious IBS. Gastroenterology 2003, 125:1651-1659.
54. Pimentel M, Chatterjee S, Chang C, et al.: Gastrointestinal infection with Campylobacter jejuni 81-176 produces altered bowel function and bacterial overgrowth in rats. Am J Gastroenterol 2006, 101:S472.
55. Malinen E, Rinttila T, Kajander K, et al.: Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005, 100:373-382.
56. O'Mahony L, McCarthy J, Kelly P, et al.: Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128:541-551.
57. Whorwell PJ, Altringer L, Morel J, et al.: Efficacy of an encapsulated probiotic Bifidobacteriurn infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006, 101:1581-1590.
58. Husebye E, Hellstrom PM, Sundler F, et al.: Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats. Am J Physiol 2001, 280: G368-G380.